On the stock market since 2021, it operates in the world of money and finance. It has 1 employee. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $210.1M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 17 buys and 12 sells. Management buying with its own money is usually read as a good sign.
A loss of $83.9M against $210.1M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, IPAX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IPAX is a high-risk stock — not yet profitable, and its future rides on its product catching on.